Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Biosimilars: Rise In US FDA Approvals Means Lower Or Flat User Fees In FY 2020
Aug 01 2019
•
By
Sue Sutter
Sponsors with approved biosimilars will shoulder more of the burden for funding the agency’s user fee program in FY 2020. • Source: Shutterstock
More from Biosimilars
More from Biosimilars & Generics